Cellectis
Iovance, Cellectis to Develop Cancer Treatment Based on Genetically-Edited Lymphocytes
The worldwide license provides Iovance Biotherapeutics exclusive rights to Cellectis' TALEN gene editing technology for multiple gene targets to modify TILs for treating various cancers.